Sands J M
Emory University School of Medicine, Renal Division, WMRB Room 338, 1639 Pierce Drive, NE, Atlanta, GA 30322, USA.
Mt Sinai J Med. 2000 Mar;67(2):112-9.
Due to urea's role in producing concentrated urine, its transport is critically important to the conservation of body water. Within the renal inner medulla, urea is transported by both facilitated and active urea transport mechanisms. The vasopressin-regulated, facilitated urea transporter (UT-A1) in the terminal inner medullary collecting duct (IMCD) permits high rates of transepithelial urea transport and results in delivery of large quantities of urea into the deepest portions of the inner medulla where it is needed to maintain a high interstitial osmolality for maximal urine concentration. Four cDNA isoforms of the UT-A urea transporter family have been cloned. In addition, there are three secondary active, sodium-dependent, urea transport mechanisms in IMCD subsegments: (1) active urea secretion in the apical membrane of the terminal IMCD from untreated rats; (2) active urea absorption in the apical membrane of the initial IMCD from low-protein fed or hypercalcemic rats; and (3) active urea absorption in the basolateral membrane of the initial IMCD from furosemide-treated rats. This review will focus on integrative studies of the rapid and long-term regulation of urea transporters in rats with reduced urine concentrating ability. These studies led to the surprising result that the basal-facilitated urea permeability in the terminal IMCD and UT-A1 protein abundance are increased during in vivo conditions associated with an impaired urine concentrating ability. In contrast, there are two response patterns of active urea transporters: (1) hypercalcemia, a low-protein diet, and furosemide result in induction of active urea absorption in the initial IMCD, albeit by different mechanisms, and inhibition of active urea secretion in the terminal IMCD; while (2) water diuresis results in up-regulation of active urea secretion in the terminal IMCD without any active urea absorption in the initial IMCD. The first pattern contributes to the urine concentrating defect by increasing urea delivery to the base of the inner medulla, thus decreasing urea delivery distally to the inner medullary tip. The second response pattern will directly decrease urea content in the deep inner medulla. UT-A urea transporters are also expressed outside the kidney. Recent studies show that the liver has phloretin-inhibitable urea transport and that it occurs via a 49 kDa UT-A protein. When rats are made uremic, the abundance of this 49 kDa UT-A protein increases in the liver in vivo. This up-regulation of the 49 kDa UT-A protein may allow hepatocytes to increase ureagenesis to reduce the accumulation of ammonium and/or bicarbonate in uremia.
由于尿素在产生浓缩尿中所起的作用,其转运对于机体水分的保存至关重要。在肾内髓质,尿素通过易化和主动转运机制进行转运。血管升压素调节的、位于终末内髓集合管(IMCD)的易化尿素转运体(UT-A1)允许高速度的跨上皮尿素转运,并导致大量尿素被输送到内髓最深部,在此处需要维持高间质渗透压以实现最大程度的尿液浓缩。已克隆出UT-A尿素转运体家族的四种cDNA亚型。此外,在IMCD各亚段存在三种继发性主动、钠依赖性尿素转运机制:(1)未处理大鼠终末IMCD顶端膜的主动尿素分泌;(2)低蛋白喂养或高钙血症大鼠初始IMCD顶端膜的主动尿素重吸收;以及(3)呋塞米处理大鼠初始IMCD基底外侧膜的主动尿素重吸收。本综述将聚焦于对尿浓缩能力降低的大鼠尿素转运体快速和长期调节的综合研究。这些研究得出了令人惊讶的结果,即在与尿浓缩能力受损相关的体内条件下,终末IMCD的基础易化尿素通透性和UT-A1蛋白丰度会增加。相比之下,主动尿素转运体有两种反应模式:(1)高钙血症、低蛋白饮食和呋塞米会导致初始IMCD中主动尿素重吸收的诱导,尽管机制不同,同时会抑制终末IMCD中的主动尿素分泌;而(2)水利尿会导致终末IMCD中主动尿素分泌上调,而初始IMCD中无任何主动尿素重吸收。第一种模式通过增加向髓质基部的尿素输送,从而减少向髓质尖端远端的尿素输送,导致尿浓缩缺陷。第二种反应模式将直接降低内髓深部的尿素含量。UT-A尿素转运体也在肾脏外表达。最近的研究表明,肝脏具有根皮素可抑制的尿素转运,且其通过一种分子量为49 kDa的UT-A蛋白发生。当大鼠发生尿毒症时,这种49 kDa的UT-A蛋白在肝脏中的丰度会在体内增加。这种49 kDa的UT-A蛋白上调可能使肝细胞增加尿素生成,以减少尿毒症时铵和/或碳酸氢盐的蓄积。